448 related articles for article (PubMed ID: 33624334)
1. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains.
Takahashi RH; Yokotsuka M; Tobiume M; Sato Y; Hasegawa H; Nagao T; Gouras GK
Brain Pathol; 2021 Sep; 31(5):e12941. PubMed ID: 33624334
[TBL] [Abstract][Full Text] [Related]
2. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
3. Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity.
Smith LM; Strittmatter SM
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 27940601
[TBL] [Abstract][Full Text] [Related]
4. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
5. Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.
Aimi T; Suzuki K; Hoshino T; Mizushima T
J Neurochem; 2015 Aug; 134(4):611-7. PubMed ID: 25963375
[TBL] [Abstract][Full Text] [Related]
6. Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease.
Nygaard HB; Strittmatter SM
Arch Neurol; 2009 Nov; 66(11):1325-8. PubMed ID: 19901162
[TBL] [Abstract][Full Text] [Related]
7. A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein.
Rösener NS; Gremer L; Reinartz E; König A; Brener O; Heise H; Hoyer W; Neudecker P; Willbold D
J Biol Chem; 2018 Oct; 293(41):15748-15764. PubMed ID: 30131337
[TBL] [Abstract][Full Text] [Related]
8. The interaction of insoluble Amyloid-β with soluble Amyloid-β dimers decreases Amyloid-β plaque numbers.
van Gerresheim EF; Herring A; Gremer L; Müller-Schiffmann A; Keyvani K; Korth C
Neuropathol Appl Neurobiol; 2021 Aug; 47(5):603-610. PubMed ID: 33338256
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain.
Takahashi RH; Tobiume M; Sato Y; Sata T; Gouras GK; Takahashi H
Neuropathology; 2011 Jun; 31(3):208-14. PubMed ID: 21062360
[TBL] [Abstract][Full Text] [Related]
10. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
11. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance.
Smith LM; Kostylev MA; Lee S; Strittmatter SM
J Biol Chem; 2019 Apr; 294(15):6042-6053. PubMed ID: 30787106
[TBL] [Abstract][Full Text] [Related]
12. Development of Alkaline Phosphatase-Fused Mouse Prion Protein and Its Application in Toxic Aβ Oligomer Detection.
Tsukakoshi K; Kubo R; Ikebukuro K
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498917
[TBL] [Abstract][Full Text] [Related]
13. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
14. The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β.
Iida M; Mashima T; Yamaoki Y; So M; Nagata T; Katahira M
FEBS J; 2019 Jun; 286(12):2355-2365. PubMed ID: 30916478
[TBL] [Abstract][Full Text] [Related]
15. Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation.
Bove-Fenderson E; Urano R; Straub JE; Harris DA
J Biol Chem; 2017 Oct; 292(41):16858-16871. PubMed ID: 28842494
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.
Chen RJ; Chang WW; Lin YC; Cheng PL; Chen YR
ACS Chem Neurosci; 2013 Sep; 4(9):1287-96. PubMed ID: 23805846
[TBL] [Abstract][Full Text] [Related]
17. Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a
Younan ND; Chen KF; Rose RS; Crowther DC; Viles JH
J Biol Chem; 2018 Aug; 293(34):13090-13099. PubMed ID: 29887525
[TBL] [Abstract][Full Text] [Related]
18. Preferential Recruitment of Conformationally Distinct Amyloid-β Oligomers by the Intrinsically Disordered Region of the Human Prion Protein.
Madhu P; Mukhopadhyay S
ACS Chem Neurosci; 2020 Jan; 11(1):86-98. PubMed ID: 31808343
[TBL] [Abstract][Full Text] [Related]
19. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.
Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T
BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660
[TBL] [Abstract][Full Text] [Related]
20. Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy.
König AS; Rösener NS; Gremer L; Tusche M; Flender D; Reinartz E; Hoyer W; Neudecker P; Willbold D; Heise H
J Biol Chem; 2021; 296():100499. PubMed ID: 33667547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
